Stockscreener 앱 받기
2.54
4.10%
0.10
시간 외 거래:
2.43
-0.11
-4.33%
전일 마감가:
$2.44
열려 있는:
$2.48
하루 거래량:
73,421
Relative Volume:
0.16
시가총액:
$11.15M
수익:
$20,000
순이익/손실:
$-10.84M
주가수익비율:
-0.9118
EPS:
-2.7857
순현금흐름:
$-10.07M
1주 성능:
-11.19%
1개월 성능:
+21.53%
6개월 성능:
-6.62%
1년 성능:
-8.83%
1일 변동 폭
$2.4163
$2.5611
1주일 범위
$2.35
$2.77
52주 변동 폭
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
명칭
Kiora Pharmaceuticals Inc
전화
858-224-9600
주소
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.54 | 10.71M | 20,000 | -10.84M | -10.07M | -2.7857 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
A light-activated eye drug cleared Phase 1 safety and moved into Phase 2 - Stock Titan
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Breakouts Watch: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Trend Recap: Will Kiora Pharmaceuticals Inc outperform its industry peers2026 Sentiment & Daily Profit Maximizing Tips - baoquankhu1.vn
Profit Review: Is Kiora Pharmaceuticals Inc a cyclical or defensive stock2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
KPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
KPRX Faces Tumultuous Trading: Strategic Moves Amid Market Fluctuations - timothysykes.com
Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally? - Bitget
KiORa Pharmaceuticals (KPRX) Stock: Jumps 24% After $24M Private Placement Deal - parameter.io
Kiora Pharmaceuticals closes $24M private placement By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade
Kiora Pharmaceuticals Inc. Poised for Strategic Expansion Amid Market Challenges - timothysykes.com
According to the latest filings disclosed by the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Kiora Pharmaceuticals (stock code: KPRX) plans to privately place 438,471 shares of its common stock to specific investors. - Bitget
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing - TipRanks
Kiora Pharmaceuticals IncEnters Securities Purchase Agreement On April 3, 2026SEC Filing - TradingView — Track All Markets
Kiora Pharmaceuticals closes $24M private placement - Investing.com
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Kiora Pharmaceuticals Raises $5 Million in Private Placement With $19 Million Warrant Upside - TradingView — Track All Markets
Kiora (NASDAQ: KPRX) secures up to $24M in milestone-based private placement - Stock Titan
Two biotech investors back Kiora with $5M now, $19M more later - Stock Titan
Critical Outcome Technologies (OTCMKTS:COTQF) and Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Survey - Defense World
Kiora Pharmaceuticals Announces Chief Development Officer Resignation - TipRanks
Kiora Pharmaceuticals chief development officer to depart - Investing.com
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora Pharmaceuticals (KPRX) CFO uses 929 shares to cover taxes - Stock Titan
Kiora (NASDAQ: KPRX) executive uses 929 shares to satisfy tax withholding - Stock Titan
Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress - Stock Titan
Kiora says retinal disease trials keep enrolling after exec exit - Stock Titan
KPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Kiora Pharmaceuticals Inc outperform its industry peersProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Should I hold or sell Kiora Pharmaceuticals Inc nowQuarterly Market Review & Accurate Trade Setup Notifications - baoquankhu1.vn
Kiora Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Kiora Pharmaceuticals reports $10.8M loss for 2025 By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Bitget
Kiora Pharmaceuticals reports $10.8M loss for 2025 - Investing.com
Kiora Pharmaceuticals posts 2025 net loss as expenses rise - TradingView
Kiora Pharmaceuticals 10-K: $0M Revenue, $(10.84)M Net Loss - TradingView
Kiora (NASDAQ: KPRX) posts 2025 loss while funding two active Phase 2 trials - Stock Titan
Retinal disease pipeline at Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan
Sectors Review: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
KPRX Should I Buy - Intellectia AI
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (NASDAQ: KPRX) CFO granted new stock and option awards - Stock Titan
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Kiora Pharmaceuticals (KPRX) CDO uses 238 shares to cover tax withholding - Stock Titan
Kiora Pharmaceuticals (KPRX) CEO disposes 238 shares for taxes - Stock Titan
KPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):